A universal platform for TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling

Adoptive T-cell therapies using tumour-specific T-cell receptors (TCRs) are limited by competition with endogenous receptors, impairing efficacy and posing risks of off-target autoreactivity. Here we present a CRISPR-based platform that selectively eliminates both endogenous TCR-α and -β chains without affecting transgenic TCRs, irrespective of codon optimization. This approach achieves >90% deletion efficiency in Jurkat and primary human T cells, enhancing expression and functional potency of transgenic receptors. Using an HLA-A*02:01-restricted DMF5 TCR, we show that dual TCR ablation boosts antigen-specific activation and cytotoxicity in vitro and enhances tumor clearance in vivo in human immune system (HIS) mice and prevents graft-versus-host disease (GVHD). Targeted locus amplification showed that CRISPR-induced double-strand breaks did not alter lentiviral integration profiles, supporting genomic safety. Extending this approach to four insulin-reactive TCRs demonstrated that endogenous receptor removal increased transduction efficiency and functional activity, with one (1E6) showing selective activation and infiltration of islet grafts (SC-islets) in vivo. This study establishes a universal, safe, and scalable genome-editing platform for generating functionally precise human T cells. By integrating cancer immunotherapy and autoimmune disease modelling within a single framework, it provides a preclinical rationale for dual endogenous TCR removal to improve specificity, safety, and therapeutic efficacy in TCR-based cell therapies.

Authors

Institutions

Publication Details

Journal
JCI Insight
Published
2026-11-17
DOI
https://doi.org/10.1172/jci.insight.201920
Citations
1
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
2.12

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A universal platform for TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling

Sameena Nikhat, Farshid Fathi, Andrew Kelvin Sewell, Klaus H. Kaestner et al.
1 citations
JCI Insight
CAR-T cell therapy research
2.12
article

A universal platform for TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling

Sameena Nikhat, Farshid Fathi, Andrew Kelvin Sewell, Klaus H. Kaestner, Mohsen Khosravi‐Maharlooei, Audrey V. Parent, Austin Chen, Daniel Traum, Megan Sykes, Edwin Bremer, Mateusz Legut, Giorgia Zanetti, Xiaolan Ding, A. C. Chen, Rémi J. Creusot, Nathan Suek, Hao Wei Li, Farshid Fathi, Mohsen Khosravi Maharlooei, Klaus Kaestner, Nato Teteloshvili, Ryan E. Hoang
article en
1 citations

Abstract

Adoptive T-cell therapies using tumour-specific T-cell receptors (TCRs) are limited by competition with endogenous receptors, impairing efficacy and posing risks of off-target autoreactivity. Here we present a CRISPR-based platform that selectively eliminates both endogenous TCR-α and -β chains without affecting transgenic TCRs, irrespective of codon optimization. This approach achieves >90% deletion efficiency in Jurkat and primary human T cells, enhancing expression and functional potency of transgenic receptors. Using an HLA-A*02:01-restricted DMF5 TCR, we show that dual TCR ablation boosts antigen-specific activation and cytotoxicity in vitro and enhances tumor clearance in vivo in human immune system (HIS) mice and prevents graft-versus-host disease (GVHD). Targeted locus amplification showed that CRISPR-induced double-strand breaks did not alter lentiviral integration profiles, supporting genomic safety. Extending this approach to four insulin-reactive TCRs demonstrated that endogenous receptor removal increased transduction efficiency and functional activity, with one (1E6) showing selective activation and infiltration of islet grafts (SC-islets) in vivo. This study establishes a universal, safe, and scalable genome-editing platform for generating functionally precise human T cells. By integrating cancer immunotherapy and autoimmune disease modelling within a single framework, it provides a preclinical rationale for dual endogenous TCR removal to improve specificity, safety, and therapeutic efficacy in TCR-based cell therapies.

JCI Insight
Mayo Clinic (US), University Medical Center Groningen (NL), University of Groningen (NL), University of California, San Francisco (US), Columbia University Irving Medical Center (US), Mayo Clinic in Arizona (US), Mayo Clinic Hospital (US), Columbia University (US), Cardiff University (GB), University of Pennsylvania (US)
American Diabetes Association, Wellcome Trust, Human Islet Research Network, National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources
Good health and well-being
Openalex Percentile: Top 18%
CAR-T cell therapy research
2.12
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon